 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H17N |
| Molar mass | 163.264 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Methylmethamphetamine (3-MMA) or Metaphedrine is an amphetamine derivative which has been sold as a designer drug, first being reported in Sweden in 2021. [1]
The European Union Drugs Agency (EUDA), known until 2024 as the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), is an agency of the European Union headquartered in Lisbon, Portugal, and established in 1993.
Adult lifetime cannabis use by country is the lifetime prevalence of cannabis use among all adults in surveys among the general population. Lifetime prevalence means any use of cannabis during a person's life.
The drug policy of Portugal, informally called the "drug strategy", was put in place in 2000, and came into effect in July 2001. Created by the Decree-Law n. 130 -A/2001 and under the jurisdiction of the Commissions for the Dissuasion of Drug Addiction, its purpose was to reduce the number of new HIV/AIDS cases in the country, as it was estimated around half of new cases came from injection drug use. This new approach focused on public health as opposed to public-order priorities by decriminalizing public and private use and possession of all drugs. Under this new policy when the police encounter individuals using or in possession of drugs, the substance is confiscated and the individual is referred to a Dissuasion Commission.
4-Methylmethamphetamine (4-MMA), also known as mephedrine, is a putative stimulant and entactogen drug of the amphetamine family. It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). The drug is the β-deketo analogue of mephedrone and the N-methyl analogue of 4-methylamphetamine (4-MA).
3-Methylmethcathinone (3-MMC), also known as metaphedrone, is a designer drug from the substituted cathinone family. 3-MMC is a monoamine transporter substrate that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity.
'MDMB-CHMICAa' is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.
CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Germany in February 2020. It is illegal in Finland.
5-Methylmethiopropamine is a stimulant drug which is a ring-substituted derivative of methiopropamine. It is not a substituted cathinone derivative like mephedrone, as it lacks a ketone group at the β position of the aliphatic side chain, but instead more closely resembles substituted amphetamines. It has been sold as a designer drug, first being identified in Germany in June 2020.
2C-B-aminorex (2C-B-AR) is a recreational designer drug with psychedelic effects. It is a substituted aminorex derivative which was first identified in Sweden in June 2019. Structurally, it is a hybrid of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and aminorex.
PTI-3 is an indole-3-thiazole based synthetic cannabinoid which has been sold as a designer drug. It was first identified in Hungary in 2020, and was made illegal in Italy in June 2021.
Dipyanone is an opioid analgesic which has been sold as a designer drug, first identified in Germany in 2021. It is closely related to medically used drugs such as methadone, dipipanone and phenadoxone, but is slightly less potent.
4-Propionoxy-N,N-dimethyltryptamine is a synthetic psychedelic drug from the tryptamine family with psychedelic effects, and is believed to act as a prodrug for psilocin. It produces a head-twitch response in mice. It has been sold online as a designer drug since May 2019. It was first identified as a new psychoactive substance in Sweden, in July 2019. A number of related derivatives have been synthesized as prodrugs of psilocin for medical applications.
5F-JWH-398 is a recreational designer drug which is classed as a synthetic cannabinoid. It is from the naphthoylindole family, and produces cannabis-like effects. It was legally sold in New Zealand from 2012 to 2014 under the psychoactive substances scheme but was discontinued in May 2014 following the end of the interim approval period under the Psychoactive Substances Act 2013. Subsequently, it has appeared on the illicit market around the world and was identified in Germany in May 2019.
3F-NEH (3-Fluoro-N-Ethylhexedrone) is a recreational designer drug from the substituted cathinone family, with stimulant effects. It was first identified in Sweden in October 2020.
The Trans-European Drug Information (TEDI) project is a European database compiling information from different drug checking services located on the European continent. The non-governmental organizations feeding into the database are referred to as the TEDI network.
4-Chloro-3-Methylmethcathinone (4-Cl-3-MMC) is a chemical compound from the substituted cathinone family. It has stimulant effects, and has been sold as a designer drug. It was first identified in Sweden in 2021. It is illegal in Italy and Finland, as well as under generic legislation in various other jurisdictions.
4-HO-MALT (4-hydroxy-N-methyl-N-allyltryptamine) is a tryptamine derivative which has been sold as a designer drug, first being detected in Slovenia in 2021.
3-Fluoro-N-ethylbuphedrone (3F-NEB) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug. It was first identified in Sweden in 2021.
2-Methyl-alpha-PVP (2-Me-PVP) is a substituted cathinone derivative with stimulant effects which has been sold as a designer drug. It was first identified in Sweden in 2021.
Deschloroclotizolam is a thienotriazolodiazepine derivative which has been sold as a designer drug, first being identified in Sweden in 2021.
{{cite book}}: CS1 maint: DOI inactive as of November 2024 (link)  | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |